SCHEMBL2925485

SCHEMBL2925485

COc1ccc(C#Cc2ccc(N3C[C@@H]4C[C@H]3CN4C)nn2)cc1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 12/20 0.48
KCNH2 Q12809 9/20 0.42
HSD11B1 P28845 1/20 0.41
GRM5 P41594 1/20 0.39
MCHR1 Q99705 1/20 0.38
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2924452 0.86 CHRNA7 (0.50) CHRNA7KCNH2GRM5PARP1
SCHEMBL2929680 0.86 CHRNA7 (0.62) CHRNA7KCNH2GRM5
SCHEMBL2946952 0.81 CHRNA7 (0.49) CHRNA7KCNH2GRM5PARP1
SCHEMBL2950583 0.80 CHRNA7 (0.48) CHRNA7KCNH2GRM5
SCHEMBL2944661 0.77 CHRNA7 (0.67) CHRNA7KCNH2
SCHEMBL3245826 0.76 GRM5 (0.39) GRM5MCHR1
SCHEMBL2945753 0.75 CHRNA7 (0.51) CHRNA7KCNH2PARP1
SCHEMBL2950258 0.75 CHRNA7 (0.51) CHRNA7KCNH2GRM5PARP1
SCHEMBL1449572 0.75 GRM5 (0.41) GRM5MCHR1
SCHEMBL9855024 0.74 APP (0.59) KCNH2GRM5MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866314-B1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2010-09-15 EP claimed
US-7750011-B2 Diazabicyclic aryl derivatives and their medical use NEUROSEARCH A/S (DK) 2010-07-06 US claimed
US-20080161314-A1 Novel Diazabicyclic Aryl Derivatives and Their Medical Use NEUROSEARCH A/S (DK) 2008-07-03 US claimed
EP-1866314-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-19 EP claimed
WO-2006087305-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-08-24 WO claimed
EP-1866314-B1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2010-09-15 EP disclosed
US-7750011-B2 Diazabicyclic aryl derivatives and their medical use NEUROSEARCH A/S (DK) 2010-07-06 US disclosed
US-20080161314-A1 Novel Diazabicyclic Aryl Derivatives and Their Medical Use NEUROSEARCH A/S (DK) 2008-07-03 US disclosed
EP-1866314-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-19 EP disclosed
WO-2006087305-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161314-A1 Novel Diazabicyclic Aryl Derivatives and Their Medical Use CHRNA6, CHRNA10, CHRNA2 CHRNA7 7/4885KCNH2 719/4885HSD11B1 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.